Retrospective Cohort Study
Copyright ©The Author(s) 2015.
World J Hepatol. Dec 8, 2015; 7(28): 2841-2848
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2841
Table 1 Baseline characteristics of patients who received triple therapy with pegylated interferon, ribavirin, and telaprevir or simeprevir
Unmatched patients
StandardizedPropensity score matched patients
Standardized
TelaprevirSimeprevirP valuedifferenceTelaprevirSimeprevirP valuedifference
No. of patientsn = 159n = 147n = 104n = 104
Age (yr)60 (51.0-65.0)63 (54.5-70.0)0.0020.34861.5 (53.0-65.8)60.5 (52.0-67.0)NS0.0154
Gender (male/female)77/8267/80NS0.05745/5949/55NS0.0773
Body mass index (kg/m2)23.9 (21.7-25.7)23.2 (21.1-25.0)NS0.20223.6 (21.1-25.3)23.4 (21.2-25.2)NS0.0747
Laboratory data
Level of viremia (log IU/mL)6.7 (6.3-7.0)6.8 (6.3-7.2)NS0.2106.7 (6.3-7.0)6.6 (6.2-7.1)NS0.0158
Leukocyte count (/mm3)5060 (4200-5800)4920 (4100-5800)NS0.0945000 (4200-5700)5020 (4150-5800)NS0.0272
Hemoglobin (g/dL)14.1 (13.1-15.0)13.8 (12.9-14.7)NS0.17514 (13.0-14.8)13.9 (12.9-15.0)NS0.0264
Platelet count (× 104/mm3)15 (12.5-19.8)15.1 (11.7-20.1)NS0.05315 (12.9-20.0)15.1 (11.8-20.1)NS0.0032
SNP of IL28B (TT/non-TT/unknown)99/34/2689/43/15NS0.15574/3073/31NS0.0211
Other data
Prior treatment response relapse/other43/3031/32NS0.19631/2223/20NS0.100
Table 2 Univariate and multivariate analysis of factors associated with sustained virological response following pegylated interferon, ribavirin, and telaprevir or simeprevir triple therapy
ParametersTelaprevir
Simeprevir
SVRNon-SVRP valueSVRNon-SVRP value
Unmatched patients
Univariate analysisn = 126n = 33n = 102n = 45
Age (yr)58.0 (51.0-65.0)62.0 (59.6-65.5)NS61.0 (52.8-67.3)66.0 (56.5-71.0)0.016
Gender (male/female)62/6415/18NS48/5419/26NS
Body mass index (kg/m2)23.8 (21.7-25.7)24.6 (21.7-26.0)NS23.2 (21.0-25.1)23.5 (21.3-26.0)NS
Level of viremia (log IU/mL)6.7 (6.3-7.0)6.6 (6.3-7.0)NS6.8 (6.2-7.1)6.9 (6.4-7.3)NS
Leukocyte count (/mm3)5100 (4200-5700)5100 (4400-6600)NS5000 (4300-5800)4800 (3800-5800)NS
Hemoglobin (g/dL)14.1 (13.2-15.1)14.1 (12.8-14.8)NS13.9 (13.1-14.7)13.7 (12.7-14.8)NS
Platelet count (× 104/mm3)15.0 (12.8-19.8)15.0 (12.5-20.1)NS15.3 (11.9-20.5)15.0 (11.1-18.3)NS
SNP of IL28B (TT/non-TT)84/1915/15< 0.00172/1917/24< 0.001
Multivariate analysisOdds ratio (95%CI)Odds ratio (95%CI)
SNP of IL28B (TT/non-TT)4.316 (1.804-10.327)0.0018.598 (3.388-21.817)< 0.001
Age (yr)0.933 (0.889-0.980)0.006
Level of viremia (log IU/mL)0.335 (0.157-0.715)0.005
Propensity score matched patients
Univariate analysisn = 77n = 27n = 76n = 28
Age (yr)60.0 (52.5-66.5)64.0 (60.0-65.0)NS59.0 (51.0-66.0)65.0 (56.0-71.0)0.021
Gender (male/female)33/4412/15NS37/3912/16NS
Body mass index (kg/m2)23.1 (20.6-25.0)24.0 (21.4-26.6)NS23.2 (21.3-25.1)23.6 (21.1-26.1)NS
Level of viremia (log IU/mL)6.7 (6.3-7.0)6.7 (6.4-6.9)NS6.7 (6.1-7.0)6.6 (6.3-7.2)NS
Leukocyte count (/mm3)5000 (4100-5700)5100 (4400-6700)NS5100 (4400-5900)4600 (3500-5700)NS
Hemoglobin (g/dL)14.0 (13.1-14.8)13.9 (13.0-14.9)NS14.0 (12.9-15.0)13.8 (12.9-14.7)NS
Platelet count (× 104/mm3)15.0 (12.3-19.7)15.4 (12.9-20.3)NS15.1 (11.9-20.4)15.0 (11.0-17.2)NS
SNP of IL28B (TT/non-TT)61/1613/140.00261/1512/16< 0.001
Multivariate analysisOdds ratio (95%CI)Odds ratio (95%CI)
SNP of IL28B (TT/non-TT)7.739 (2.111-28.375)0.0028.594 (2.777-26.598)< 0.001

  • Citation: Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848
  • URL: https://www.wjgnet.com/1948-5182/full/v7/i28/2841.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v7.i28.2841